author-photo

Bettina Peuser

Praxis

6

Papers

12

Citations

Citation Trend

Filter By

Papers (6) Sort By

JournalConferenceOthers

Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

2020 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (9)
Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): german AIO KRK0110 (ML22011) - study

2017 Onkologie
Show All
- Source
- Cite
- Save
Citations (0)
Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
O-026Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study.

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号